Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesEarnAISquareMore
Tether CEO Claims 1,000 Signatures Collected in Petition to Restore Satoshi Nakamoto Statue in Lugano

Tether CEO Claims 1,000 Signatures Collected in Petition to Restore Satoshi Nakamoto Statue in Lugano

ChaincatcherChaincatcher2025/08/08 07:44
Show original
Tether CEO Paolo Ardoino announced that 1,000 signatures have been collected for a petition to the Lugano city government in Switzerland, calling for the repair and restoration of the vandalized Satoshi Nakamoto statue. The statue, unveiled on October 25, 2024, during an event co-hosted by Tether and Lugano’s “Plan ₿” initiative, was designed by artist Valentina Picozzi and took 21 months to complete, symbolizing the anonymity and decentralization embodied by Bitcoin’s founder, Satoshi Nakamoto.
 
On August 2, the statue was vandalized during Swiss National Day celebrations, dismantled, and thrown into Lake Lugano. It was recovered by municipal workers on August 4. Satoshigallery has pledged to cover the restoration costs, and the community has shown strong support for restoring this Bitcoin cultural landmark.
0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Competition in US oral weight-loss drugs intensifies! Eli Lilly (LLY.US) Foundayo captures 30% of new patients, narrowing Novo Nordisk's (NVO.US) first-mover advantage

Eli Lilly stated on Monday that its oral weight-loss drug, Foundayo, has captured over 30% of the market share among new patients in the US oral obesity treatment market, narrowing the early lead achieved by Danish competitor Novo Nordisk with its Wegovy oral tablets.

智通财经2026/09/15 03:21
Competition in US oral weight-loss drugs intensifies! Eli Lilly (LLY.US) Foundayo captures 30% of new patients, narrowing Novo Nordisk's (NVO.US) first-mover advantage